Publisher: Research Institute for Gastroenterology and Liver Diseases (RIGLD)
  • Register
  • Login

Gastroenterology and Hepatology from Bed to Bench

  • Home
  • Issues
    • Current
    • Archives
  • About
    • About the Journal
    • Aims and Scope
    • Editorial Team
    • Privacy Statement
    • Contact
  • For Authors
    • Submissions
    • Author Guidelines
    • Article Processing Charge
    • Peer Review Process
  • Indexing & Abstracting
  • Announcements
Advanced Search
  1. Home
  2. Archives
  3. Vol. 10 No. 3 (2017): Vol 10, No 3 (2017):Summer
  4. Original Article

Vol. 10 No. 3 (2017)

August 2017

Regulation of HSVtk Gene by Endogenous microRNA-122a in Liver Cell Lines as Suicide Gene Therapy

  • Maryam Ghanbari
  • Esmaeil Saberfar
  • zahra goodarzi
  • Hadi Lashini
  • Sahar Ghanbari
  • Mojtaba Karamimanesh
  • Kazem Baesi

Gastroenterology and Hepatology from Bed to Bench, Vol. 10 No. 3 (2017), 5 August 2017 , Page 202-207
https://doi.org/10.22037/ghfbb.v0i0.1002 Published: 2017-08-05

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Aim: Here, we use miR-122a that exhibits liver-specific expression for developing a post-transcriptional regulative system mediated by microRNAs.

Background: Gene therapy with adenovirus (Ad) vectors that express herpes simplex virus thymidine kinase (HSVtk) and ganciclovir (GCV) have been suggested as a therapeutic strategy to cancer. However, Ad vectors injected into tumors are dispersed into the systemic circulation and transduce liver cells, resulting in severe hepatotoxicity. To be effective, the delivery and expression of suicide genes to cancer treatment ought to be specific to tumor cells, and avoid death of healthy cells. Researchers have demonstrated that expression of transgene could be suppressed in healthy cells with use of vectors that are reactive to microRNA regulation.

Methods: We constructed an Ad vector carrying four tandem copies of target sequences of miR-122a that were incorporated into 3'-UTR of HSVtk gene. The expression level of miR-122a was quantified in HepG2 and Huh7 cell lines.

Results: Quantitative RT- PCR analysis demonstrated that Huh7 cells express large amounts of miR-122a compared to HepG2 cells. The viability of Huh7 cells and HepG2 cells after infection by Ad-tk-122aT vector was 83% and 23.5%, respectively. The viability of Huh7 cells was not reduced in the presence of GCV after infection by Ad-tk-122a vector. In contrast, cytotoxicity of HSV-tk/GCV was similar in Huh7 cells and HepG2 cells by Ad-tk vector, with 35.3% and 27% viability, respectively.

Conclusion: Inclusion of the miR-122a target sequences in the HSVtk expression cassette yielded a feasible strategy for reducing cytotoxicity of suicide gene in a liver cell line with high miR-122a expression

Keywords microRNA regulation; miR-122a; HSVtk gene; ganciclovir; cancer therapy

Keywords:
  • microRNA regulation
  • miR-122a
  • HSVtk gene
  • ganciclovir
  • cancer therapy
  • PDF

How to Cite

Ghanbari, M., Saberfar, E., goodarzi, zahra, Lashini, H., Ghanbari, S., Karamimanesh, M., & Baesi, K. (2017). Regulation of HSVtk Gene by Endogenous microRNA-122a in Liver Cell Lines as Suicide Gene Therapy. Gastroenterology and Hepatology from Bed to Bench, 10(3), 202–207. https://doi.org/10.22037/ghfbb.v0i0.1002
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

Zarogoulidis P, Chatzaki E, Hohenforst-Schmidt W, Goldberg EP, Galaktidou G, Kontakiotis T, et al. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review. Cancer gene ther. 2012;19(9):593-600.

Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer gene ther. 2011;18(5):305-17.

Khare R, Y Chen C, A Weaver E, A Barry M. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther. 2011;11(4):241-58.

Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med. 2013;15(2):65-77.

Duarte S, Carle G, Faneca H, De Lima MCP, Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now? Cancer Lett. 2012;324(2):160-70.

Kelly EJ, Russell SJ. MicroRNAs and the regulation of vector tropism. Mol Ther. 2008;17(3):409-16.

Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011;18(12):1121-6.

Gentner B, Naldini L. Exploiting microRNA regulation for genetic engineering. Tissue Antigens. 2012;80(5):393-403.

Amendola M, Giustacchini A, Gentner B, Naldini L. A double-switch vector system positively regulates transgene expression by endogenous microRNA expression (miR-ON vector). Mol Ther. 2013;21(5):934-46.

Cheng CJ, Slack FJ. The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J. 2012;18(3):232.

Geisler A, Jungmann A, Kurreck J, Poller W, Katus HA, Vetter R, et al. microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther. 2011;18(2):199-209.

Bandiera S, Pfeffer Sb, Baumert TF, Zeisel MB. miR-122-A key factor and therapeutic target in liver disease. J Hepatol. 2015;62(2):448-57.

Ghanbari Safari M, Hosseinkhani S. Lipid composition of cationic nanoliposomes implicate on transfection efficiency. Journal of liposome research. 2013;23(3):174-86.

Suzuki T, Sakurai F, Nakamura S-i, Kouyama E, Kawabata K, Kondoh M, et al. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther. 2008;16(10):1719-26.

Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, et al. Downregulation of miR-122a in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006;99(3):671-8.

Akerblom M, Sachdeva R, Quintino L, Wettergren EE, Chapman KZ, Manfre G, et al. Visualization and genetic modification of resident brain microglia using lentiviral vectors regulated by microRNA-9. Nat Commun. 2013;4:1770.

Brown BD, Venneri MA, Zingale A, Sergi LS, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med. 2006;12(5):585-91.

Jopling C. Liver-specific microRNA-122: Biogenesis and function. RNA Biol. 2012;9(2):137.

Xie J, Xie Q, Zhang H, Ameres SL, Hung J-H, Su Q, et al. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol Ther. 2011;19(3):526-35.

Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, Zingale A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol. 2007;25(12):1457-67.

Safari MG, Baesi K, Hosseinkhani S. An alternative approach in regulation of expression of a transgene by endogenous miR-145 in carcinoma and normal breast cell lines. Biotechnol Appl Biochem. 2017;64(2):244-50.

Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, et al. Research Paper miR-122, a Mammalian Liver-Specific microRNA, is Processed from mRNA and May Downregulate the High Affinity Cationic Amino Acid Transporter CAT-1. RNA Biol. 2004;1:106-13.

Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol. 2008;48(4):648-56.

Iino I, Kikuchi H, Miyazaki S, Hiramatsu Y, Ohta M, Kamiya K, et al. Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis. Cancer Sci. 2013;104(5):624-30.

  • Abstract Viewed: 653 times
  • PDF Downloaded: 213 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Developed By

Open Journal Systems
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

GHFBB journal is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Print ISSN: 2008-2258
Online ISSN: 2008-4234

Support Contact: ghfbb.journal@gmail.com

Powered by OJSPlus